Changyou Zhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Changyou Zhan has a total of 367 co-authors. Here are the top co-authors by number of shared publications:
Jun Qian
20 shared publicationsTianhao Ding
Department of Pharmacology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China
14 shared publicationsErcan Wu
Department of Pharmacology, School of Basic Medical Sciences
13 shared publicationsJuan Guan
13 shared publications- Weiyue Lu
Department of Pharmaceutics, School of Pharmacy, Fudan University & Key Laboratory of Smart Drug Delivery (Fudan University), Ministry of Education, Shanghai 201203, China
12 shared publications Feng Pan
Fudan University
11 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
CRISPR/Cas based genome editing for liver diseases: Promise and challenge
- 3 October 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
Open AccessCRISPR/Cas based genome editing for liver diseases: Promise and challenge
FAPi‐Mediated siRNA Lipid Nanoparticles for the Treatment of Liver Fibrosis
Liver fibrosis lacks effective therapies largely due to the inability of conventional lipid nanoparticles (LNPs) to target activated hepatic stellate cells (HSCs), the primary drivers of fibrotic progression. Here, we developed a fibroblast activation protein inhibitor (FAPi)‐modified LNP encapsulating heat shock protein 47 (HSP47) siRNA (FAPi‐LNP/siHSP47) to target activated HSCs. FAPi‐LNP/siHSP47 exhibited enhanced HSC targeting, efficient HSP47 silencing, reduced alpha‐smooth muscle actin (α‐SMA) expression, and marked attenuation of collagen deposition in vivo. Pharmacokinetic and protein corona analyses revealed that DSPE‐PEG‐based LNPs displayed prolonged circulation and increased area under the curve (AUC) compared with DMG‐PEG formulations, while FAPi modification further enhanced AUC and reduced adsorption of complement protein C3 and apolipoprotein E (ApoE), thereby decreasing hepatocyte uptake. Importantly, acute toxicity evaluation demonstrated favorable in vivo biocompatibility without hematological, inflammatory, or histopathological abnormalities. Collectively, FAPi modification enabled LNPs to specifically target activated HSCs, providing a safe and effective treatment for liver fibrosis and presenting a new strategy for directing LNPs to cells beyond hepatocytes.
FAPi‐Mediated siRNA Lipid Nanoparticles for the Treatment of Liver Fibrosis
Liver fibrosis lacks effective therapies largely due to the inability of conventional lipid nanoparticles (LNPs) to target activated hepatic stellate cells (HSCs), the primary drivers of fibrotic progression. Here, we developed a fibroblast activation protein inhibitor (FAPi)‐modified LNP encapsulating heat shock protein 47 (HSP47) siRNA (FAPi‐LNP/siHSP47) to target activated HSCs. FAPi‐LNP/siHSP47 exhibited enhanced HSC targeting, efficient HSP47 silencing, reduced alpha‐smooth muscle actin (α‐SMA) expression, and marked attenuation of collagen deposition in vivo. Pharmacokinetic and protein corona analyses revealed that DSPE‐PEG‐based LNPs displayed prolonged circulation and increased area under the curve (AUC) compared with DMG‐PEG formulations, while FAPi modification further enhanced AUC and reduced adsorption of complement protein C3 and apolipoprotein E (ApoE), thereby decreasing hepatocyte uptake. Importantly, acute toxicity evaluation demonstrated favorable in vivo biocompatibility without hematological, inflammatory, or histopathological abnormalities. Collectively, FAPi modification enabled LNPs to specifically target activated HSCs, providing a safe and effective treatment for liver fibrosis and presenting a new strategy for directing LNPs to cells beyond hepatocytes.
- Open Access
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77691
Collagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity
The immunosuppressive microenvironment limits immunotherapy in triple‐negative breast cancer (TNBC). Interleukin‐15 (IL‐15) activates cytotoxic lymphocytes but is limited by rapid clearance and poor tumor retention. Here, we developed an oncolytic adenovirus encoding IL15C‐CBD, an immunocytokine comprising an IL‐15/IL‐15Rα sushi‐domain complex fused to a collagen‐binding domain, thereby establishing a self‐reinforcing immunostimulatory milieu within tumors. Intratumoral administered OV‐IL15C‐CBD lyses tumor cells and secretes IL15C‐CBD that anchors to extracellular matrix collagens, forming a localized cytokine reservoir. In the murine 4T1 TNBC model, this strategy profoundly remodeled the microenvironment by recruiting CD8 + T cells and natural killer cells, depleting regulatory T cells, and polarizing macrophages. toward an M1‐like phenotype. Consequently, OV‐IL15C‐CBD induced significant tumor regression and extended survival without evident systemic toxicity. This therapeutic advantage was further validated in the EMT6 breast tumor model, yielding consistent antitumor efficacy and prolonged survival. Collectively, anchoring immunocytokines to the tumor stroma via oncolytic viruses provides a potentially safe and effective localized immunotherapy for TNBC.
- 16 September 2026
- Published by Wiley in Advanced Science
- p. e77691
Open AccessCollagen‐Binding IL‐15 Immunocytokine Armed Oncolytic Adenovirus Establishes a Self‐Reinforcing Immunostimulatory Milieu to Potentiate Antitumor Immunity
The immunosuppressive microenvironment limits immunotherapy in triple‐negative breast cancer (TNBC). Interleukin‐15 (IL‐15) activates cytotoxic lymphocytes but is limited by rapid clearance and poor tumor retention. Here, we developed an oncolytic adenovirus encoding IL15C‐CBD, an immunocytokine comprising an IL‐15/IL‐15Rα sushi‐domain complex fused to a collagen‐binding domain, thereby establishing a self‐reinforcing immunostimulatory milieu within tumors. Intratumoral administered OV‐IL15C‐CBD lyses tumor cells and secretes IL15C‐CBD that anchors to extracellular matrix collagens, forming a localized cytokine reservoir. In the murine 4T1 TNBC model, this strategy profoundly remodeled the microenvironment by recruiting CD8 + T cells and natural killer cells, depleting regulatory T cells, and polarizing macrophages. toward an M1‐like phenotype. Consequently, OV‐IL15C‐CBD induced significant tumor regression and extended survival without evident systemic toxicity. This therapeutic advantage was further validated in the EMT6 breast tumor model, yielding consistent antitumor efficacy and prolonged survival. Collectively, anchoring immunocytokines to the tumor stroma via oncolytic viruses provides a potentially safe and effective localized immunotherapy for TNBC.
- 25 July 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (31) , 22215-22232
Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines
Clinical translation of nanomedicines is greatly hindered by insufficient understanding of their in vivo process, yet a key challenge lies in quantifying the encapsulated versus free drug forms in tissues and cells. Herein, we present a facile, versatile anti-PEG single-chain variable-fragment antibody (PEG-scFv)-based method enabling quantitative measurement of both forms in various biofluids (e.g., interstitial fluid, cytoplasm). By this method, we map the in vivo process of PEGylated liposomal doxorubicin (sLip/Dox) at unprecedented resolution. In the bloodstream, doxorubicin remains largely encapsulated in liposomes (>99%). In liver as the main organ for drug elimination, less drug was distributed in the interstitium (>80% encapsulated) but more in liver cells (mainly in Kupffer cells) released in a time-dependent manner, accompanying doxorubicin transferred to hepatocytes most in free form by 12 h postinjection. After extravasation into tumors, there was a limited access of sLip/Dox to tumor cells, confining most of the drug in the interstitium mainly being encapsulated (more than 75%), and the internalized fraction underwent a gradual release process in both tumor-associated macrophages and tumor cells. These findings revealed that for sLip/Dox, which primarily underwent drug release intracellularly, cellular internalization rates could be the key factor in determining its in vivo performance. Given widespread PEGylation on developing nanomedicines and the cost-effectiveness of scFv production, PEG-scFv offers a broadly applicable tool for dissecting in vivo processes of nanomedicines to establish dose–effect relationships like small-molecule drugs, further to guide rational nanotherapeutic design.
- 25 July 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (31) , 22215-22232
Anti-PEG Single-Chain Variable-Fragment Antibody-Assisted In Vivo Process Decoding of PEGylated Nanomedicines
Clinical translation of nanomedicines is greatly hindered by insufficient understanding of their in vivo process, yet a key challenge lies in quantifying the encapsulated versus free drug forms in tissues and cells. Herein, we present a facile, versatile anti-PEG single-chain variable-fragment antibody (PEG-scFv)-based method enabling quantitative measurement of both forms in various biofluids (e.g., interstitial fluid, cytoplasm). By this method, we map the in vivo process of PEGylated liposomal doxorubicin (sLip/Dox) at unprecedented resolution. In the bloodstream, doxorubicin remains largely encapsulated in liposomes (>99%). In liver as the main organ for drug elimination, less drug was distributed in the interstitium (>80% encapsulated) but more in liver cells (mainly in Kupffer cells) released in a time-dependent manner, accompanying doxorubicin transferred to hepatocytes most in free form by 12 h postinjection. After extravasation into tumors, there was a limited access of sLip/Dox to tumor cells, confining most of the drug in the interstitium mainly being encapsulated (more than 75%), and the internalized fraction underwent a gradual release process in both tumor-associated macrophages and tumor cells. These findings revealed that for sLip/Dox, which primarily underwent drug release intracellularly, cellular internalization rates could be the key factor in determining its in vivo performance. Given widespread PEGylation on developing nanomedicines and the cost-effectiveness of scFv production, PEG-scFv offers a broadly applicable tool for dissecting in vivo processes of nanomedicines to establish dose–effect relationships like small-molecule drugs, further to guide rational nanotherapeutic design.
- Open Access
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8438
Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection
Pulmonary bacterial infections remain a major clinical challenge. Although vaccination reduces infection rates and mortality, the vulnerable post-vaccination immunity gap can still result in infection and vaccine failure. In addition, effective vaccines are unavailable for many clinically important bacterial pathogens. Here, we report a pulmonary mRNA-lipid nanoparticle (mRNA-LNP) vaccine incorporating an ionizable lipid engineered for localized high-level expression, which elicits both rapid and durable protection against bacterial lung infections in female mice, effectively bridging this critical window of vulnerability. Intratracheal delivery of mRNA-LNP rapidly primes lung neutrophils and macrophages into a transcriptionally pre-activated state, enhancing their phagocytic activity and enabling rapid, antigen-independent bacterial clearance during the early post-vaccination period (approximately 1-7 days). Subsequently, vaccination induces potent antigen-specific adaptive responses, conferring sustained protection against both laboratory and clinical drug-resistant Pseudomonas aeruginosa strains. Single-cell transcriptomics and immune profiling reveal coordinated activation of innate and adaptive immune programs. This dual-phase immune response exemplifies a paradigm-shifting vaccine design that integrates innate and adaptive immunity to confer both immediate and long-term protection. Our findings establish a mechanistic basis for rapid antibacterial defense and highlight pulmonary mRNA-LNP vaccination as a promising strategy for combating respiratory infections.
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8438
Open AccessPulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection
Pulmonary bacterial infections remain a major clinical challenge. Although vaccination reduces infection rates and mortality, the vulnerable post-vaccination immunity gap can still result in infection and vaccine failure. In addition, effective vaccines are unavailable for many clinically important bacterial pathogens. Here, we report a pulmonary mRNA-lipid nanoparticle (mRNA-LNP) vaccine incorporating an ionizable lipid engineered for localized high-level expression, which elicits both rapid and durable protection against bacterial lung infections in female mice, effectively bridging this critical window of vulnerability. Intratracheal delivery of mRNA-LNP rapidly primes lung neutrophils and macrophages into a transcriptionally pre-activated state, enhancing their phagocytic activity and enabling rapid, antigen-independent bacterial clearance during the early post-vaccination period (approximately 1-7 days). Subsequently, vaccination induces potent antigen-specific adaptive responses, conferring sustained protection against both laboratory and clinical drug-resistant Pseudomonas aeruginosa strains. Single-cell transcriptomics and immune profiling reveal coordinated activation of innate and adaptive immune programs. This dual-phase immune response exemplifies a paradigm-shifting vaccine design that integrates innate and adaptive immunity to confer both immediate and long-term protection. Our findings establish a mechanistic basis for rapid antibacterial defense and highlight pulmonary mRNA-LNP vaccination as a promising strategy for combating respiratory infections.
- 9 June 2026
- Published by American Chemical Society (ACS) in ACS Nano
Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies
Polyethylene glycol (PEG) has been extensively utilized in food, cosmetics, and pharmaceutical fields, especially in the realm of nanomedicines, where it serves as a pivotal excipient to prolong the nanoparticles' circulation half-life. Contrary to its historical perception as being nonimmunogenic, pre-existing anti-PEG antibodies have been widely detected in human even in individuals without prior exposure to PEGylated therapeutics and are associated with clinically relevant adverse effects of PEGylated nanomedicines including infusion reactions and hypersensitive reactions. Herein, we elucidated the prevalence and distribution characteristics of pre-existing anti-PEG antibodies in 1970 human blood samples and investigated its binding with PEG. The binding between pre-existing anti-PEG IgM and PEG was modulated by PEG terminal chemistry, with methoxy groups enhancing overall antibody-PEG interactions. Notably, methoxy is the only terminal configuration used in currently marketed PEGylated nanomedicines. In contrast, hydroxy PEG (OH-PEG) significantly evaded binding with pre-existing anti-PEG IgM among most clinical samples from three independent hospitals. Noteworthily, replacing methoxy PEG (MeO-PEG) with OH-PEG significantly attenuated complement activation of lipid nanoparticle (LNP) caused by pre-existing anti-PEG IgM, thereby markedly enhancing stability and reducing mRNA leakage in human serum. Additionally, LNP modified with OH-PEG exhibited reduced immunogenicity, which is crucial for repeated administrations. Collectively, this study elucidated the crucial role of OH-PEG in evading human pre-existing anti-PEG antibodies and discovered that the current preclinical studies inadequately simulated the biological effects of clinical pre-existing anti-PEG antibodies on such formulations through interspecies study, which had a profound impact on clinical translation of PEGylated nanomedicines.
- 9 June 2026
- Published by American Chemical Society (ACS) in ACS Nano
Hydroxyl-Terminated Polyethylene Glycol Evades Human Pre-existing Anti-polyethylene Glycol Antibodies
Polyethylene glycol (PEG) has been extensively utilized in food, cosmetics, and pharmaceutical fields, especially in the realm of nanomedicines, where it serves as a pivotal excipient to prolong the nanoparticles' circulation half-life. Contrary to its historical perception as being nonimmunogenic, pre-existing anti-PEG antibodies have been widely detected in human even in individuals without prior exposure to PEGylated therapeutics and are associated with clinically relevant adverse effects of PEGylated nanomedicines including infusion reactions and hypersensitive reactions. Herein, we elucidated the prevalence and distribution characteristics of pre-existing anti-PEG antibodies in 1970 human blood samples and investigated its binding with PEG. The binding between pre-existing anti-PEG IgM and PEG was modulated by PEG terminal chemistry, with methoxy groups enhancing overall antibody-PEG interactions. Notably, methoxy is the only terminal configuration used in currently marketed PEGylated nanomedicines. In contrast, hydroxy PEG (OH-PEG) significantly evaded binding with pre-existing anti-PEG IgM among most clinical samples from three independent hospitals. Noteworthily, replacing methoxy PEG (MeO-PEG) with OH-PEG significantly attenuated complement activation of lipid nanoparticle (LNP) caused by pre-existing anti-PEG IgM, thereby markedly enhancing stability and reducing mRNA leakage in human serum. Additionally, LNP modified with OH-PEG exhibited reduced immunogenicity, which is crucial for repeated administrations. Collectively, this study elucidated the crucial role of OH-PEG in evading human pre-existing anti-PEG antibodies and discovered that the current preclinical studies inadequately simulated the biological effects of clinical pre-existing anti-PEG antibodies on such formulations through interspecies study, which had a profound impact on clinical translation of PEGylated nanomedicines.
- 28 May 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 396, 115057
Dexamethasone ameliorates dermatologic adverse effects of PEGylated liposomal doxorubicin
- 28 May 2026
- Published by Elsevier in Journal of Controlled Release
- Vol. 396, 115057
Dexamethasone ameliorates dermatologic adverse effects of PEGylated liposomal doxorubicin
- Open Access
- 29 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Polyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy
Long-acting formulations are increasingly sought after for the management of chronic diseases. Drug-conjugated microparticles with degradation-controlled release present a promising modular extended-release platform that can be delivered through minimally invasive approaches. However, many conventional drug-conjugated microparticles have relatively short durations of release and substantial release of pharmacologically inactive drug-conjugated oligomers. Here, we present surface-erodible, drug-conjugated polyketal microparticles for extended release of unmodified pharmacologically active drug. Microparticles made of a polyketal conjugated to the anti-glaucoma agent tafluprost initially release unmodified tafluprost, then about two weeks later predominantly release the biologically active tafluprost acid due to the mildly base-catalyzed hydrolysis of tafluprost, with a cumulative total drug release of ~78% over 540 days in vitro. Notably, no detectable drug-conjugated oligomers are found in release medium. Tafluprost-polyketal conjugate microparticles that further encapsulate unconjugated tafluprost reduce intraocular pressure for approximately 3 months after subconjunctival injection in ocular normotensive female rats, exhibiting a low grade of tissue reaction, no retinal abnormalities or systemic side effects, and enhanced intraocular pressure-lowering efficacy compared with a long-acting bimatoprost-loaded biodegradable implant in an ocular hypertensive rat model. Our findings have broad implications in advancing extended drug delivery systems.
- 29 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessPolyketal-conjugated tafluprost microparticles enable long-acting glaucoma therapy
Long-acting formulations are increasingly sought after for the management of chronic diseases. Drug-conjugated microparticles with degradation-controlled release present a promising modular extended-release platform that can be delivered through minimally invasive approaches. However, many conventional drug-conjugated microparticles have relatively short durations of release and substantial release of pharmacologically inactive drug-conjugated oligomers. Here, we present surface-erodible, drug-conjugated polyketal microparticles for extended release of unmodified pharmacologically active drug. Microparticles made of a polyketal conjugated to the anti-glaucoma agent tafluprost initially release unmodified tafluprost, then about two weeks later predominantly release the biologically active tafluprost acid due to the mildly base-catalyzed hydrolysis of tafluprost, with a cumulative total drug release of ~78% over 540 days in vitro. Notably, no detectable drug-conjugated oligomers are found in release medium. Tafluprost-polyketal conjugate microparticles that further encapsulate unconjugated tafluprost reduce intraocular pressure for approximately 3 months after subconjunctival injection in ocular normotensive female rats, exhibiting a low grade of tissue reaction, no retinal abnormalities or systemic side effects, and enhanced intraocular pressure-lowering efficacy compared with a long-acting bimatoprost-loaded biodegradable implant in an ocular hypertensive rat model. Our findings have broad implications in advancing extended drug delivery systems.
- Open Access
- 19 March 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 7001-7018
Effects of anti-PEG antibodies on extravascular transport of stealth liposome: A study on interspecies differences
- 19 March 2026
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (10) , 7001-7018
Open AccessEffects of anti-PEG antibodies on extravascular transport of stealth liposome: A study on interspecies differences
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (9)
Standardizing pre-existing anti-PEG antibody detection: A key to clarifying their binding features and clinical relevance
- 17 March 2026
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (9)
Open AccessStandardizing pre-existing anti-PEG antibody detection: A key to clarifying their binding features and clinical relevance